Factory Price Powder Isoniazid CAS NO (54-85-3) In Bulk

1. Introduction to Isoniazid (CAS number 54-85-3): Isoniazid is a crucial first-line medication used in the treatment of tuberculosis (TB), a contagious bacterial infection primarily affecting the lungs. With the CAS number 54-85-3, it stands as a cornerstone of TB therapy, contributing significantly to global efforts to combat this infectious disease.

2. Chemical Structure and Composition: At its molecular level, isoniazid features a hydrazide functional group (-NH-NH2) attached to an isonicotinic acid moiety. This structural configuration confers specific antimicrobial properties crucial for its therapeutic efficacy against Mycobacterium tuberculosis, the causative agent of TB.

3. Mechanism of Action: Isoniazid exerts its antimycobacterial activity by inhibiting the synthesis of mycolic acids, essential components of the mycobacterial cell wall. By disrupting cell wall integrity, isoniazid interferes with bacterial growth and replication, effectively targeting and eradicating M. tuberculosis infections.

4. Tuberculosis Treatment: Isoniazid serves as a cornerstone of TB treatment, forming the backbone of standard short-course chemotherapy regimens recommended by the World Health Organization (WHO). It is typically administered in combination with other anti-TB drugs, such as rifampicin, pyrazinamide, and ethambutol, in various treatment phases to achieve optimal therapeutic outcomes.

5. Drug Resistance and Treatment Challenges: Despite its efficacy, the emergence of drug-resistant strains of M. tuberculosis poses significant challenges to TB control efforts. Isoniazid resistance, either as monoresistance or multidrug resistance (MDR-TB), necessitates the use of alternative drug regimens and intensified surveillance to combat treatment failures and prevent further transmission.

6. Tuberculosis Prevention: Isoniazid is also utilized in TB preventive therapy (TPT) regimens, particularly in individuals at high risk of developing active TB disease, such as close contacts of TB patients and persons with latent TB infection (LTBI). TPT aims to reduce the risk of TB progression and transmission, contributing to TB control and elimination efforts.

7. Pharmacokinetics and Adverse Effects: Following oral administration, isoniazid is rapidly absorbed and distributed throughout the body, reaching therapeutic concentrations in target tissues. Common adverse effects include hepatotoxicity, peripheral neuropathy, and gastrointestinal disturbances, necessitating close monitoring and management during treatment.

8. Public Health Impact and Global Health Initiatives: Isoniazid plays a pivotal role in global TB control initiatives aimed at reducing TB incidence, morbidity, and mortality worldwide. Through comprehensive TB treatment programs, including directly observed therapy (DOTS), preventive therapy, and drug resistance surveillance, isoniazid contributes to achieving TB elimination goals.

9. Challenges and Opportunities in TB Management: Despite significant progress, challenges such as treatment adherence, healthcare infrastructure limitations, and socioeconomic disparities persist in TB management. Ongoing research into novel treatment strategies, point-of-care diagnostics, and health system strengthening initiatives offer opportunities to enhance TB control efforts and improve patient outcomes.

10. Future Directions and Research Priorities: Future research endeavors in TB management aim to address unmet needs in drug development, diagnostics, and treatment optimization. Strategies focusing on personalized medicine, host-directed therapies, and novel drug targets hold promise for advancing TB care and achieving sustainable TB control on a global scale.